Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myositis Ossificans | 4 | 2023 | 77 | 2.850 |
Why?
|
| Ossification, Heterotopic | 3 | 2023 | 235 | 1.830 |
Why?
|
| Fibrous Dysplasia, Polyostotic | 2 | 2024 | 36 | 1.760 |
Why?
|
| Niemann-Pick Disease, Type C | 2 | 2023 | 49 | 1.730 |
Why?
|
| Pain | 15 | 2024 | 5063 | 1.670 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2024 | 53 | 0.900 |
Why?
|
| Neuralgia | 3 | 2024 | 600 | 0.820 |
Why?
|
| Somatosensory Disorders | 1 | 2022 | 49 | 0.790 |
Why?
|
| Somatoform Disorders | 1 | 2024 | 423 | 0.760 |
Why?
|
| Osteochondrodysplasias | 1 | 2022 | 182 | 0.760 |
Why?
|
| Lysosomal Storage Diseases | 1 | 2021 | 79 | 0.750 |
Why?
|
| Nerve Net | 5 | 2021 | 2264 | 0.730 |
Why?
|
| Endocrine System Diseases | 1 | 2023 | 249 | 0.720 |
Why?
|
| Brain | 15 | 2021 | 26950 | 0.710 |
Why?
|
| Opioid-Related Disorders | 3 | 2022 | 2141 | 0.690 |
Why?
|
| Neuromuscular Diseases | 1 | 2021 | 255 | 0.610 |
Why?
|
| Pain Measurement | 8 | 2022 | 3523 | 0.600 |
Why?
|
| Reward | 2 | 2021 | 965 | 0.580 |
Why?
|
| Central Nervous System Diseases | 1 | 2021 | 519 | 0.570 |
Why?
|
| Magnetic Resonance Imaging | 28 | 2023 | 36271 | 0.570 |
Why?
|
| Buprenorphine | 4 | 2013 | 654 | 0.560 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2024 | 2387 | 0.550 |
Why?
|
| Activins | 1 | 2017 | 210 | 0.520 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2022 | 4562 | 0.500 |
Why?
|
| Analgesia | 2 | 2017 | 459 | 0.480 |
Why?
|
| Hot Temperature | 4 | 2015 | 1434 | 0.440 |
Why?
|
| Auditory Cortex | 2 | 2008 | 362 | 0.440 |
Why?
|
| Sciatic Neuropathy | 1 | 2013 | 75 | 0.430 |
Why?
|
| Executive Function | 1 | 2021 | 1375 | 0.420 |
Why?
|
| Child Abuse | 1 | 2022 | 1068 | 0.420 |
Why?
|
| Mental Disorders | 2 | 2023 | 6802 | 0.410 |
Why?
|
| Neuropharmacology | 1 | 2011 | 20 | 0.390 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2024 | 2159 | 0.380 |
Why?
|
| Psychotic Disorders | 1 | 2024 | 3197 | 0.330 |
Why?
|
| Brain Mapping | 10 | 2018 | 6571 | 0.310 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2009 | 246 | 0.300 |
Why?
|
| Neural Pathways | 4 | 2021 | 3040 | 0.300 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2008 | 2782 | 0.300 |
Why?
|
| Wakefulness | 2 | 2011 | 1256 | 0.290 |
Why?
|
| Afferent Pathways | 1 | 2008 | 298 | 0.290 |
Why?
|
| Trigeminal Nerve | 1 | 2008 | 248 | 0.280 |
Why?
|
| Analgesics, Opioid | 3 | 2013 | 3762 | 0.270 |
Why?
|
| Analgesics | 2 | 2020 | 1064 | 0.260 |
Why?
|
| Spectrum Analysis | 1 | 2007 | 451 | 0.250 |
Why?
|
| Aspartic Acid | 1 | 2007 | 576 | 0.250 |
Why?
|
| Action Potentials | 1 | 2012 | 1816 | 0.240 |
Why?
|
| Osteoarthritis | 1 | 2012 | 1056 | 0.240 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 1878 | 0.240 |
Why?
|
| Humans | 45 | 2024 | 757650 | 0.220 |
Why?
|
| Brain Stem | 1 | 2008 | 857 | 0.220 |
Why?
|
| Corpus Callosum | 1 | 2007 | 749 | 0.210 |
Why?
|
| Sulfonamides | 1 | 2012 | 1972 | 0.210 |
Why?
|
| Pyrazoles | 1 | 2012 | 1994 | 0.200 |
Why?
|
| Inflammation | 1 | 2022 | 10718 | 0.200 |
Why?
|
| Myography | 1 | 2022 | 111 | 0.200 |
Why?
|
| Catastrophization | 1 | 2024 | 347 | 0.180 |
Why?
|
| Activin Receptors, Type I | 1 | 2021 | 136 | 0.180 |
Why?
|
| Spinal Cord | 1 | 2008 | 1815 | 0.180 |
Why?
|
| Adolescent | 8 | 2024 | 87832 | 0.180 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2015 | 8945 | 0.170 |
Why?
|
| Post-Traumatic Headache | 1 | 2021 | 65 | 0.170 |
Why?
|
| Motor Skills Disorders | 1 | 2020 | 89 | 0.170 |
Why?
|
| Models, Neurological | 2 | 2022 | 1757 | 0.170 |
Why?
|
| Axons | 1 | 2007 | 1674 | 0.160 |
Why?
|
| Adult | 17 | 2024 | 219747 | 0.160 |
Why?
|
| Putamen | 1 | 2020 | 291 | 0.160 |
Why?
|
| Psychopathology | 1 | 2022 | 429 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2008 | 3338 | 0.160 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2020 | 121 | 0.160 |
Why?
|
| Electric Impedance | 1 | 2022 | 754 | 0.150 |
Why?
|
| Child | 6 | 2024 | 79787 | 0.150 |
Why?
|
| Diphosphonates | 1 | 2023 | 636 | 0.150 |
Why?
|
| Rare Diseases | 1 | 2023 | 618 | 0.150 |
Why?
|
| Muscles | 1 | 2022 | 1575 | 0.150 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 18123 | 0.150 |
Why?
|
| Cerebrum | 1 | 2018 | 132 | 0.140 |
Why?
|
| Comorbidity | 2 | 2022 | 10478 | 0.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 3757 | 0.140 |
Why?
|
| Male | 24 | 2024 | 358227 | 0.140 |
Why?
|
| Avoidance Learning | 1 | 2018 | 248 | 0.140 |
Why?
|
| Age of Onset | 1 | 2024 | 3296 | 0.140 |
Why?
|
| Central Nervous System | 1 | 2024 | 1332 | 0.140 |
Why?
|
| Cerebellum | 1 | 2023 | 1497 | 0.130 |
Why?
|
| Prefrontal Cortex | 2 | 2021 | 2209 | 0.130 |
Why?
|
| Lysosomes | 1 | 2021 | 919 | 0.130 |
Why?
|
| Drug Design | 2 | 2011 | 1049 | 0.130 |
Why?
|
| X-Ray Microtomography | 1 | 2017 | 443 | 0.120 |
Why?
|
| Blood-Brain Barrier | 1 | 2021 | 1018 | 0.120 |
Why?
|
| Rats | 5 | 2013 | 23681 | 0.120 |
Why?
|
| Phenotype | 2 | 2023 | 16533 | 0.110 |
Why?
|
| Young Adult | 6 | 2024 | 58764 | 0.110 |
Why?
|
| Autophagy | 1 | 2021 | 1322 | 0.110 |
Why?
|
| Oxygen | 4 | 2015 | 4190 | 0.110 |
Why?
|
| Nalbuphine | 1 | 2013 | 20 | 0.110 |
Why?
|
| Fluorescence Polarization | 1 | 2013 | 140 | 0.110 |
Why?
|
| Acoustic Stimulation | 2 | 2008 | 1232 | 0.110 |
Why?
|
| Knee Joint | 1 | 2021 | 1664 | 0.100 |
Why?
|
| Bone and Bones | 1 | 2023 | 2559 | 0.100 |
Why?
|
| Administration, Sublingual | 1 | 2011 | 58 | 0.100 |
Why?
|
| Drug Discovery | 2 | 2017 | 1044 | 0.100 |
Why?
|
| Gyrus Cinguli | 2 | 2023 | 1115 | 0.100 |
Why?
|
| Cross-Over Studies | 3 | 2013 | 2048 | 0.100 |
Why?
|
| Pulvinar | 1 | 2011 | 21 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2013 | 10750 | 0.090 |
Why?
|
| Rats, Long-Evans | 1 | 2011 | 378 | 0.090 |
Why?
|
| Caregivers | 1 | 2023 | 2224 | 0.090 |
Why?
|
| Rats, Inbred Lew | 1 | 2012 | 1154 | 0.090 |
Why?
|
| Touch | 2 | 2010 | 312 | 0.090 |
Why?
|
| Respiratory Rate | 1 | 2011 | 175 | 0.090 |
Why?
|
| Guidelines as Topic | 3 | 2011 | 1384 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2022 | 8551 | 0.090 |
Why?
|
| Clinical Trials as Topic | 3 | 2011 | 7982 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2015 | 2922 | 0.080 |
Why?
|
| Brain Concussion | 1 | 2021 | 1397 | 0.080 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 1379 | 0.080 |
Why?
|
| Trigeminal Neuralgia | 1 | 2010 | 106 | 0.080 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2010 | 195 | 0.080 |
Why?
|
| Trigeminal Nucleus, Spinal | 1 | 2008 | 21 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2024 | 54108 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2015 | 2357 | 0.080 |
Why?
|
| Female | 11 | 2024 | 389985 | 0.080 |
Why?
|
| Neurosciences | 1 | 2013 | 353 | 0.080 |
Why?
|
| Animals | 9 | 2017 | 167777 | 0.080 |
Why?
|
| Proteomics | 1 | 2022 | 3816 | 0.080 |
Why?
|
| Triazines | 1 | 2010 | 310 | 0.080 |
Why?
|
| Physical Stimulation | 1 | 2009 | 518 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2013 | 1955 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2013 | 8145 | 0.070 |
Why?
|
| Optic Nerve | 1 | 2011 | 567 | 0.070 |
Why?
|
| Basal Ganglia | 1 | 2010 | 553 | 0.070 |
Why?
|
| Pharmaceutical Preparations | 2 | 2017 | 1088 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2008 | 642 | 0.070 |
Why?
|
| Visual Pathways | 1 | 2011 | 534 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2015 | 6231 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 15782 | 0.070 |
Why?
|
| Parietal Lobe | 1 | 2011 | 849 | 0.070 |
Why?
|
| Hypothalamus | 1 | 2011 | 998 | 0.070 |
Why?
|
| Diffusion | 1 | 2007 | 812 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 25931 | 0.060 |
Why?
|
| Ketamine | 1 | 2010 | 516 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2013 | 12260 | 0.050 |
Why?
|
| Nerve Fibers | 1 | 2006 | 708 | 0.050 |
Why?
|
| Amygdala | 1 | 2010 | 1351 | 0.050 |
Why?
|
| Quality of Life | 1 | 2024 | 13265 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2008 | 956 | 0.050 |
Why?
|
| Probability | 1 | 2006 | 2461 | 0.050 |
Why?
|
| Functional Laterality | 1 | 2008 | 2252 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2010 | 1882 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 20499 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 20039 | 0.040 |
Why?
|
| Brain Diseases | 1 | 2008 | 1541 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2022 | 42044 | 0.040 |
Why?
|
| Quality Control | 2 | 2011 | 825 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2013 | 2212 | 0.040 |
Why?
|
| Middle Aged | 5 | 2022 | 219219 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 6457 | 0.040 |
Why?
|
| Hand Strength | 1 | 2020 | 452 | 0.040 |
Why?
|
| Anxiety | 1 | 2011 | 4533 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2007 | 2880 | 0.030 |
Why?
|
| Mutation | 1 | 2021 | 29928 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2011 | 5756 | 0.030 |
Why?
|
| Drug Industry | 2 | 2011 | 787 | 0.030 |
Why?
|
| Software | 1 | 2006 | 4416 | 0.030 |
Why?
|
| Psychophysics | 1 | 2013 | 289 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 79982 | 0.020 |
Why?
|
| Receptors, Opioid, mu | 1 | 2013 | 166 | 0.020 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2012 | 132 | 0.020 |
Why?
|
| Photophobia | 1 | 2011 | 71 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 81107 | 0.020 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2011 | 162 | 0.020 |
Why?
|
| Naloxone | 1 | 2013 | 369 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 2010 | 377 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2010 | 272 | 0.020 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2010 | 140 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 41198 | 0.020 |
Why?
|
| Amines | 1 | 2010 | 281 | 0.020 |
Why?
|
| Species Specificity | 1 | 2013 | 2416 | 0.020 |
Why?
|
| Cold Temperature | 1 | 2010 | 780 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 1661 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 1713 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2010 | 960 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2010 | 1132 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2010 | 1489 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2010 | 6012 | 0.010 |
Why?
|
| Decision Making | 1 | 2012 | 3909 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2010 | 6198 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 9460 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 13952 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 39815 | 0.000 |
Why?
|
| Aged | 1 | 2020 | 167889 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2010 | 64242 | 0.000 |
Why?
|
| United States | 1 | 2008 | 71907 | 0.000 |
Why?
|
Concepts
(192)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(54)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_